Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › hepatic impairment

Hepatic impairment

Part of Liver disease

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for hepatic impairment

42 trials tracked for hepatic impairment: 2 in phase 3 or 4 and 1 with published results.

42Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 2 1 Phase 1 39
  1. Phase 4 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed
  2. Phase 4 An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers Completed
  3. Phase 2 A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers Completed
  4. Phase 1 Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) Completed
  5. Phase 1 PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers Completed
  6. Phase 1 A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Completed
Show 36 more trials
  1. Phase 1 Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib Completed
  2. Phase 1 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers Completed
  3. Phase 1 A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012) Completed
  4. Phase 1 A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. Completed
  5. Phase 1 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Completed
  6. Phase 1 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Completed
  7. Phase 1 Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects Completed
  8. Phase 1 Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite Completed
  9. Phase 1 Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment Completed
  10. Phase 1 Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects Completed
  11. Phase 1 Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function Completed
  12. Phase 1 A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction Completed
  13. Phase 1 A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function Completed
  14. Phase 1 A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 Completed
  15. Phase 1 Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK Completed
  16. Phase 1 Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment Completed
  17. Phase 1 Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects Completed
  18. Phase 1 Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment Completed
  19. Phase 1 A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function Completed
  20. Phase 1 Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment Completed
  21. Phase 1 Study of Nalbuphine ER in Participants With Hepatic Impairment Completed
  22. Phase 1 A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants Completed
  23. Phase 1 Tepotinib Hepatic Impairment Trial Completed
  24. Phase 1 Pharmacokinetics of BAF312 in Patients With Hepatic Impairment Completed
  25. Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Completed
  26. Phase 1 Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Completed
  27. Phase 1 A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) Completed
  28. Phase 1 STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT Completed
  29. Phase 1 A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT Completed
  30. Phase 1 Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 Completed
  31. Phase 1 Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Completed
  32. Phase 1 A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function Completed
  33. Phase 1 A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) Completed
  34. Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment Completed
  35. Phase 1 A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment Completed
  36. Phase 1 A Hepatic Impairment Study for PF-04965842. Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment
Drug Pipeline Sys. Review
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment New Dose Rules for Niraparib in Liver Disease Protect Patients
This systematic review uses physiologically based pharmacokinetic (PBPK) modeling to predict optimal niraparib dosing in patients with hepat…
A smart computer model now shows how to safely lower niraparib doses for cancer patients with liver disease, protecting them from harmful si…
Frontiers May 11, 2026
Single 6 mg erdafitinib dose shows similar pharmacokinetics in mild or moderate hepatic impairment versus healthy controls
Gastroenterology Phase I
Single 6 mg erdafitinib dose shows similar pharmacokinetics in mild or moderate hepatic impairment versus healthy controls Single dose of erdafitinib showed no dose changes needed for mild or moderate liver issues
This Phase 1 open-label single-dose study evaluated pharmacokinetics of erdafitinib in 26 participants with hepatic impairment versus health…
A single dose of erdafitinib worked well in people with mild or moderate liver problems, showing no need for dose adjustments.
May 1, 2026